ADC Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NYSE:ADCT Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
11 Dec 24	BuyUS$228,000	Redmile Group, LLC	Company	100,000	US$2.28
11 Dec 24	BuyUS$381,000	Redmile Group, LLC	Company	100,000	US$3.81
04 Dec 24	SellUS$52,479	Redmile Group, LLC	Company	25,352	US$2.07
01 Jul 24	BuyUS$2,248,000	Redmile Group, LLC	Company	800,000	US$2.81
17 Jun 24	SellUS$20,216	Victor Sandor	Individual	6,995	US$2.89
17 Jun 24	SellUS$4,153	Thomas Pfisterer	Individual	1,437	US$2.89
17 Jun 24	SellUS$4,153	Viviane Monges	Individual	1,437	US$2.89
17 Jun 24	SellUS$3,448	Peter Hug	Individual	1,193	US$2.89
17 Jun 24	SellUS$20,216	Jean-Pierre Bizzari	Individual	6,995	US$2.89
17 Jun 24	SellUS$20,216	Ron Squarer	Individual	6,995	US$2.89
17 Jun 24	SellUS$20,216	Robert Azelby	Individual	6,995	US$2.89
07 May 24	SellUS$133,195	Ameet Mallik	Individual	29,731	US$4.48
17 Apr 24	SellUS$41,440	Stephen Evans-Freke	Individual	8,500	US$5.04

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of ADCT?
Owner Type	Number of Shares	Ownership Percentage
Public Companies	4,011,215	4.15%
Individual Insiders	6,165,660	6.38%
Private Companies	9,678,085	10%
General Public	17,606,155	18.2%
Hedge Funds	25,302,968	26.2%
Institutions	33,925,534	35.1%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.7%.

Top Shareholders

Top 25 shareholders own 76.68% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
16.2%	Redmile Group, LLC	15,666,731	US$30.7m	-0.02%	1.88%
9.97%	Prosight Management, LP	9,636,237	US$18.9m	0.69%	5.61%
7.71%	Hpwh Th Ag	7,450,000	US$14.6m	0%	no data
4.69%	OrbiMed Advisors LLC	4,533,801	US$8.9m	5.03%	0.14%
4.55%	BlackRock, Inc.	4,399,134	US$8.6m	23.8%	no data
4.15%	Brookfield Corporation	4,017,013	US$7.9m	0%	0.03%
4.15%	AstraZeneca PLC	4,011,215	US$7.9m	0%	no data
3.14%	Morgan Stanley, Investment Banking and Brokerage Investments	3,039,045	US$6.0m	2.79%	no data
2.58%	Bank of America Corporation, Asset Management Arm	2,496,652	US$4.9m	105%	no data
2.42%	Hans-Peter Wild	2,338,944	US$4.6m	0%	no data
2.3%	Adc Products Switzerland S.A.R.L	2,228,085	US$4.4m	0%	no data
1.86%	Silverarc Capital Management, LLC	1,795,080	US$3.5m	1.49%	0.91%
1.72%	Goldman Sachs Group, Investment Banking and Securities Investments	1,664,581	US$3.3m	9.17%	no data
1.6%	Ron Squarer	1,545,007	US$3.0m	3,700%	no data
1.49%	Platinum Investment Management Limited	1,444,516	US$2.8m	11.4%	0.11%
1.2%	Artal Group S.A.	1,163,461	US$2.3m	14.2%	0.07%
1.14%	State Street Global Advisors, Inc.	1,106,011	US$2.2m	11.6%	no data
0.99%	Geode Capital Management, LLC	953,171	US$1.9m	15.6%	no data
0.96%	Ameet Mallik	929,005	US$1.8m	-6.34%	no data
0.88%	Vantage Consulting Group, Inc.	850,737	US$1.7m	0%	18.71%
0.76%	Blue Owl Capital, Investment Arm	733,568	US$1.4m	0%	0.61%
0.74%	Millennium Management LLC	712,401	US$1.4m	-12.7%	no data
0.56%	The Vanguard Group, Inc.	539,359	US$1.1m	33.4%	no data
0.5%	Northern Trust Global Investments	481,037	US$942.8k	1,990%	no data
0.42%	GCM Grosvenor Inc.	410,888	US$805.3k	0%	0.11%

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/23 08:11
End of Day Share Price	2024/12/20 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ADC Therapeutics SA is covered by 18 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Tazeen Ahmad	BofA Global Research
Lut Ming Cheng	Cantor Fitzgerald & Co.
Eric Schmidt	Cantor Fitzgerald & Co.